Scientific publications

Vaccination for Pancreatic Ductal Adenocarcinoma: A Hard Nut to Crack

Salas-Benito D (1,2), Melero I (2,3,4), Ponz-Sarvise M (5,4,6).

(1) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(2) Program of Immunology and Immunotherapy, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.
(3) Department of Immunology and Immunotherapy, Clinica Universidad de Navarra, Pamplona, Spain.
(4) IdiSNA, Navarra Institute for Health Research, Pamplona, Spain.
(5) Department of Medical Oncology, Clinica Universidad de Navarra, Pamplona, Spain.
(6) Program in Solid Tumors and Biomarkers, Center for Applied Medical Research (CIMA), University of Navarra, Pamplona, Spain.

Magazine: Clinical Cancer Research

Date: Sep 15, 2019

Immunology [SP] Medical Oncology

No immunotherapy strategy is yet offering consistent results against pancreatic ductal adenocarcinoma. A randomized clinical trial testing repeated immunization with a Listeria monocytogenes-based vaccine encoding for mesothelin in combination with a GM-CSF-transfected allogeneic pancreatic cell vaccine reports no survival benefit for the vaccinated patients.See related article by Le et al., p. 5493.

CITATION  Clin Cancer Res. 2019 Sep 15;25(18):5435-5437. doi: 10.1158/1078-0432.CCR-19-1753. Epub 2019 Jul 17

you maybe interested

WHAT TECHNOLOGY
DO WE USE?

The Clínica is the greater private hospital with technological equipment of Spain, all in a single center.

Imagen de un PET, tecnología de vanguardia en la Clínica Universidad de Navarra

OUR
PROFESSIONALS

The professionals of the Clínica perform continuous research and training, always to the benefit of the patient.

Imagen profesionales de la Clínica Universidad de Navarra

WHY CHOOSE
THE CLINICA?

Learn why we are different from other healthcare centers. Quality, speed, comfort and results.

Imagen del edificio de la Clínica Universidad de Navarra